Dmitry Bobylev, Alexander Horke, Murat Avsar, Tomislav Cvitkovic, Dietmar Boethig, Mark Hazekamp, Bart Meyns, Filip Rega, Hitendu Dave, Martin Schmiady, Anatol Ciubotaru, Eduard Cheptanaru, Vladimiro Vida, Massimo Padalino, Victor Tsang, Ramadan Jashari, Günther Laufer, Martin Andreas, Alexandra Andreeva, Igor Tudorache, Serghei Cebotari, Axel Haverich, Samir Sarikouch
For decades, bovine jugular vein conduits (BJV) and classic cryopreserved homografts have been the two most widely used options for pulmonary valve replacement (PVR) in congenital heart disease. More recently, decellularized pulmonary homografts (DPH) have provided an alternative avenue for PVR. Matched comparison of patients who received DPH for PVR with patients who received bovine jugular vein conduits (BJV) considering patient age group, type of heart defect, and previous procedures. 319 DPH patients were matched to 319 BJV patients; the mean age of BJV patients was 15...
March 14, 2023: Cell and Tissue Banking